United Therapeutics Corporation
NASDAQ:UTHRBiotechnology
-$18.01 today
- Market cap
- $24.59B
- Beta
- 0.57
- P/E (TTM)
- 18.0
- EPS (TTM)
- $29.60
Volume 0.42M
Average 0.52M
UTHR EBITDA Margin
EBITDA as a percentage of revenue.
United Therapeutics CorporationNASDAQ: UTHR
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin narrows to 51.0%
EBITDA Margin was 51.0% in Q2 FY2026, down 3.7 pp from a year earlier. On a trailing-twelve-month basis it was 53.1%, down 2.6 pp year over year. Over 3 fiscal years it widened by 3.4 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 52.0% for the fiscal year ending Dec 2026, down from 57.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 51.0%+7.0 pp QoQ
- Last fiscal yearDec 2025
- 57.2%-0.3 pp YoY
- LTMJun 2026
- 53.1%-2.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -3.7 pp | -9.4 pp | -5.8 pp |
| 1 year | -0.3 pp | -5.1 pp | -4.8 pp |
| 3 years | +3.4 pp | +9.8 pp | +6.4 pp |
| 5 years | +2.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 57.2%
- Year-over-year change
- -0.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 57.2% | -0.3pp |
| FY2024 | 2024-12-31 | 57.5% | -2.1pp |
| FY2023 | 2023-12-31 | 59.6% | +5.9pp |
| FY2022 | 2022-12-31 | 53.7% | +10.0pp |
| FY2021 | 2021-12-31 | 43.7% | — |
EBITDA Margin vs competitors
How UTHR compares with its peers on the latest reported figures
- UTHR's LTM Jun 2026 EBITDA Margin of 53.1% is the highest of the 4 companies compared; the peer median is -16.4%.
- Its year-over-year change of -2.6 pp is the 3rd highest of 4, against a peer median of +167.9 pp.
- Over three fiscal years its change of +3.4 pp compares with a peer median of +192.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 53.1% | -2.6 pp | +3.4 pp | |
| LTM Jun 2026 | 39.4% | +670.4 pp | +192.5 pp | |
| LTM Sep 2026 | -16.4% | -11.2 pp | +278.1 pp | |
| LTM Jun 2026 | -67.8% | +167.9 pp | -10.9 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding UTHR) | -16.4% | +167.9 pp | +192.5 pp | |
Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.69B | 1.94B | 2.33B | 2.88B | 3.18B |
| Cost of Revenue | 122.5M | 146.7M | 257.5M | 309.7M | 384.4M |
| Gross Profit | 1.56B | 1.79B | 2.07B | 2.57B | 2.8B |
| Gross Margin | 92.7% | 92.4% | 88.9% | 89.2% | 87.9% |
| Research & Development | 540.1M | 322.9M | 408M | 481M | 550M |
| Selling, General & Admin | 467M | 487M | 477.1M | 638.6M | 731.1M |
| Operating Expenses | 1.01B | 809.9M | 885.1M | 1.19B | 1.28B |
| Depreciation & Amortization | 49.9M | 51.3M | 53.2M | 72.5M | 85.6M |
| EBITDA | 736.8M | 1.04B | 1.39B | 1.65B | 1.82B |
| EBITDA Margin | 43.7% | 53.7% | 59.6% | 57.5% | 57.2% |
| Operating Income | 555.9M | 979.7M | 1.18B | 1.38B | 1.52B |
| Operating Margin | 33.0% | 50.6% | 50.9% | 47.9% | 47.7% |
| Interest Income | 16.7M | 45.2M | 162.7M | 199.1M | 192M |
| Interest Expense | 18.6M | 32.4M | 59.3M | 42.9M | 19.5M |
| Other Income / Expenses | 38M | (29.1M) | 89.4M | 162M | 196.7M |
| Income Before Tax | 593.9M | 950.6M | 1.27B | 1.54B | 1.71B |
| Pre-Tax Margin | 35.2% | 49.1% | 54.7% | 53.5% | 53.9% |
| Income Tax Expense | 118.1M | 223.3M | 289.5M | 343.9M | 379.2M |
| Net Income | 475.8M | 727.3M | 984.8M | 1.2B | 1.33B |
| Net Margin | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
| EPS (Basic) | 10.60 | 15.98 | 21.04 | 26.44 | 30.13 |
| EPS (Diluted) | 10.06 | 15.00 | 19.81 | 24.64 | 27.86 |
| Weighted Avg Shares | 44.9M | 45.5M | 46.8M | 45.2M | 44.3M |
| Weighted Avg Shares (Diluted) | 47.3M | 48.5M | 49.7M | 48.5M | 47.9M |
United Therapeutics Corporation
NASDAQ:UTHR
Intrinsic Alpha fair value
Locked
Current Price
$577.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.